Harrow rolls out ordering portal for atropine formulations

According to the company, compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. The prescriptions will be dispensed through Harrow’s wholly owned subsidiary, ImprimisRx.

Harrow today announced the launch of atropine.com, an ordering and marketing portal that is designed specifically for prescribers interested in compounded atropine formulations. All atropine.com prescriptions will be dispensed through Harrow’s wholly owned subsidiary, ImprimisRx.

“For many years, customers have consistently told us of their growing need for a trusted and reliable source of compounded atropine,” Mark L. Baum, chairman and CEO of Harrow, said in a statement. “A recent article highlighted that the quality of available compounded atropine formulations varies greatly, causing inconsistency in stability, potency, storage requirements, and product shelf life.”

Baum pointed out that the company saw an opportunity to resolve these issues, create a family of compounded formulations of atropine, and support patients and eyecare professionals with customer service.

“Our compounded atropine formulations undergo a strict series of validated analytical tests to ensure consistency, potency, and stability; they are stable at a biologically comfortable pH and are now available in three concentrations (0.01%, 0.025%, and 0.05%) for as low as $39 per bottle,” he said.

Moreover, Baum pointed out in the statement that while Harrow’s current suite of compounded atropine formulations is available for individual patients through the ImprimisRx 503A national mail-order pharmacy, the comapny intends to make a patent‑pending suite of compounded atropine formulations that does not contain either preservatives or boric acid. 

“This suite of products will be available soon to healthcare facilities through our 503B outsourcing facility – with or without a patient-specific prescription,” he said in the news release.

Compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. Eyecare professionals can prescribe atropine for individual patients online at atropine.com or by calling ImprimisRx Customer Care at 844-446‑6979. Healthcare providers may sign up for updates on the availability of atropine formulations through the ImprimisRx FDA-registered and FDA-inspected 503B outsourcing facility.